ArticleResearch square2026
Metabolic-vascular burden and subsequent Parkinson's disease across Chinese, English, and European ageing cohorts.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Background: Metabolic and vascular disorders have been linked to Parkinson's disease (PD), but population-based evidence remains inconsistent. We examined whether harmonized metabolic-vascular burden was associated with subsequent reported PD across Chinese, English, and European ageing cohorts. Methods: We analyzed participants aged 50 years or older in CHARLS, ELSA, and SHARE after excluding reported PD at exposure baseline. Metabolic-vascular burden was scored from 0 to 4 by summing diabetes, hypertension, dyslipidemia or high cholesterol, and body mass index > = 25 kg/m2. Subsequent reported PD was identified at follow-up waves. Cohort-specific logistic regression estimated odds ratios (ORs) per additional component, followed by random-effects meta-analysis. Results: The analytic sample included 111,142 participants and 1,332 follow-up PD events: 16,531 participants and 241 events in CHARLS, 13,581 and 134 in ELSA, and 81,030 and 957 in SHARE. In demographic-adjusted models, each additional component was associated with higher PD odds in CHARLS (OR 1.29, 95% CI 1.14-1.47) and SHARE (OR 1.13, 95% CI 1.07-1.20), but not ELSA (OR 1.03, 95% CI 0.85-1.25). The pooled demographic-adjusted OR was 1.16 (95% CI 1.04-1.29; I2 = 59.5%). Fully adjusted estimates were attenuated (pooled OR 1.07, 95% CI 0.90-1.28). Component models implicated diabetes and dyslipidemia in CHARLS and diabetes and BMI > = 25 kg/m2 in SHARE. Conclusions: Metabolic-vascular burden showed a modest, heterogeneous association with subsequent reported PD. The findings support interpreting cardiometabolic-PD associations as population-context dependent rather than as a single transportable risk estimate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.